The year 2017 was a year dominated by large-scale clinical studies reporting the outcome of various interventions in cardiac surgery and heart failure (HF) patients, relevant to all cardiothoracic anesthesiologists. Among them were studies investigating the addition of levosimendan, an alternative inotropic agent, to standard management of patients with HF undergoing cardiac surgery. Also, corticosteroids have been used for various purposes in cardiac patients. Here, a new study reports the effect of high-dose methylprednisolone on recovery and delirium. Furthermore, with increasing evidence that transfusions increase morbidity and mortality, a publication reports the use of rotational thromboelastometry to reduce transfusion requirements. In addition, several randomized controlled multicenter studies report the outcomes of patients undergoing cardiac procedures: surgical versus transcatheter aortic valve replacement in intermediate-risk patients and the use of centrifugal-flow versus axial-flow left-ventricular devices in patients with HF. These studies demonstrate the dynamic and ever-evolving state of perioperative cardiovascular medicine and show us the direction of future developments.
Introduction
The specialty of cardiothoracic anesthesia is rapidly advancing, with new evolving therapeutic strategies. The year 2017 yielded a number of clinical studies in the fields of transfusion medicine, antiarrhythmic therapy, cardiocirculatory assist devices, new inotropic medication, and outcome data on transcatheter valve replacement. We will present articles that we found may have an impact on how we treat our patients. It is important to note that we are clearly not able to present all interesting and important articles published in 2017, but we identified 9 studies that cover topics of relevance for the cardiothoracic anesthesiologist (Table 1) . Furthermore, for more in-depth information we refer the reader to the original publications.
Three multicenter, randomized controlled, doubleblinded studies, the CHEETAH, the LICORN, and the LEVO-CTS trial, report the results of the use of levosimendan in addition to standard medical treatment of patients with severe heart failure (HF) that underwent cardiac surgery. [1] [2] [3] Corticosteroid use in patients undergoing cardiac surgery is cyclical. Therefore, we present a study investigating the effect of high-dose methylprednisolone on delirium and recovery after cardiac surgery. 4 As an estimated 20% of the units of blood in the United States are transfused to cardiac surgery patients and transfusion is associated with morbidity and mortality, we reference a study in our review that uses rotational thromboelastometry (ROTEM) intraoperatively to reduce blood transfusions. 5 Cardiothoracic anesthesiologists are involved in surgical and transcatheter aortic valve replacements (SAVRs and TAVRs). The indications for TAVR are more widely defined nowadays, extending to intermediate-risk patients, with trials under way for low-risk patients. We, therefore, present 2 studies reporting 2-year outcome data on intermediaterisk patients undergoing TAVR or SAVR. 6, 7 Last, but not least, we would like to introduce the reader to 2 studies comparing axial-flow left-ventricular assist devices (LVADs) with newer centrifugal-flow LVADs with regard to 6-month and 2-year outcomes, especially the incidence of stroke, pump thrombosis, sepsis, and right HF. We hope you enjoy reading the summaries of these articles as much as we did browsing the 2017 literature. 
Levosimendan in Cardiac Surgery
The cardiac anesthesiologist is quite often confronted with patients whose LVEF is severely compromised secondary to HF. These patients almost always require inotropes postoperatively and frequently also preoperatively. Levosimendan is currently being used in more than 60 countries worldwide for HF and acute perioperative leftventricular dysfunction. The principle mechanism of action is distinct from that of other inotropes because it is a calcium-sensitizing agent, promoting the binding of calcium to troponin C and stabilizing actin-myosin crossbridges. It increases cardiac output with minimal effects on myocardial oxygen consumption; it has anti-inflammatory and direct cardioprotective effects. The vasodilatory effects are mediated through levosimendan's ATP-sensitive potassium-channel opening capabilities. Previous studies have reported beneficial effects of levosimendan on renal function, hemodynamics, and mortality in patients undergoing cardiac surgery. [8] [9] [10] [11] We summarize 3 remarkable studies-all of them multicenter, randomized, doubleblind, and placebo-controlled-investigating the effects of levosimendan for patients with left-ventricular dysfunction in the perioperative period after heart surgery: The Levosimendan to Reduce Mortality in High Risk Cardiac Surgery Patients: A Multicenter Randomized Controlled Trial (CHEETAH), 1 the Levosimendan in Coronary Artery Revascularization Trial (LICORN), 2 
and the Levosimendan in Patients with Left Ventricular Systolic Dysfunction
Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. 3 Landoni et al 1 included a total of 506 patients with ongoing left-ventricular dysfunction undergoing cardiac surgery in the CHEETAH trial.
1 Left-ventricular dysfunction as inclusion criterion was defined as a left-ventricular ejection fraction (LVEF) <25% or the preoperative use of or the need for an intra-aortic balloon pump (IABP), or high-dose inotropic support. The primary outcome was 30-day mortality. Secondary outcomes consisted of acute kidney injury (AKI), the need for renal-replacement therapy (RRT), duration of mechanical ventilation, and intensive care unit (ICU) and hospital length-of-stay (LOS). The investigator planned to enroll 500 patients in both the levosimendan and the placebo group. However, after interim analysis, the study was stopped for futility after 248 were randomized 1:1 to levosimendan and 258 to receive placebo. The study drug was started at a dose of 0.05 µg/kg/min and titrated up or down to effect (minimum dose: 0.025 µg/kg/min; maximum dose: 0.2 µg/kg/ min) for up to 48 hours or discharge from the ICU. No bolus was administered. Whereas the mean infusion duration was comparable between the 2 groups (levosimendan: 33 ± 14.6 hours, placebo: 32 ± 13.5 hours; P = .17), the mean (equivalent) doses differed (levosimendan: 0.066 ± 0.031 µg/kg/min; equivalent dose placebo: 0.075 ± 0.033 µg/kg/min; P = .002). No differences existed in the use of vasoactive drugs and the hemodynamic variables. The authors were unable to find a difference in the ; P = .97), nor were any significant differences in the secondary outcomes found. There were no differences in the incidence of hypotension and arrhythmias between the groups. In about half of the patients, the cardiac output was measured; however, no difference existed between the levosimendan and the placebo group. The study was unable to detect a statistically significant effect of levosimendan on 30-day mortality, AKI, the need for RRT, duration of mechanical ventilation, and ICU and hospital LOS in patients with ongoing left-ventricular dysfunction undergoing cardiac surgery. The patients underwent a vast spectrum of different procedures (eg, isolated coronary artery bypass grafting [CABG] , isolated valve surgery, combination of CABG with valve surgery, aortic surgery, and combinations of different valve surgeries), with only a relatively small number in each group; therefore, it is impossible to predict which patient group, if any, would have benefited the most from levosimendan. A bolus of levosimendan was omitted in this study to avoid hypotension, but the number of attempts to increase the dose in the placebo group suggests some hemodynamic effect of levosimendan. The results of this study do not support the addition of levosimendan to the therapeutic management of patients with perioperative left-ventricular dysfunction.
In the LICORN trial, Cholley et al 2 try to answer the question of whether a 24-hour infusion of levosimendan in the immediate postoperative phase in patients with an LVEF <40% undergoing heart surgery (either CABG alone or CABG combined with a valvular procedure) can prevent the occurrence or mitigate low cardiac output syndrome. Therefore, 333 patients with the inclusion criteria of CABG surgery with cardiopulmonary bypass (CPB) alone or in combination with valve surgery and a reduced LVEF <40% were randomized to either placebo or levosimendan. The study drug was initiated after induction of anesthesia at a dose of 0.1 µg/kg/min without a bolus, and the infusion was terminated after 24 hours. The primary outcome was a composite of catecholamine infusion for >48 hours after study drug initiation, the need for cardiocirculatory assist devices, or the need for RRT at any time during the ICU stay. Secondary outcomes were mortality (in-hospital, 30-day, 180-day), number of days needing cardiovascular support (cardiocirculatory assist device, catecholamine infusion), number of RRT kits used, ventilator-free days, out-of-ICU and out-of-hospital days at day 28, and ICU and hospital LOS. In all, 74% of patients underwent CABG only and 26% had combined surgery, with no differences in treatment allocation.
There were no differences in the primary end point between the 2 treatment groups in the intention-to-treat analysis (levosimendan: 87 patients [52%]; placebo: 101 patients [61%]; absolute risk difference: −7%; 95% CI = −17% to 3%; P = .15) or the per-protocol analysis (levosimendan: 81 patients [51%]; placebo: 95 patients [61%]; absolute risk difference: −8%; 95% CI = −18% to 3%; P = .14). The most frequently occurring component of the primary outcome was catecholamine infusion for >48 hours after study initiation, not significantly affected by levosimendan (absolute risk difference: −8%; 95% CI = −18 to 1%; P = .09). The 2 groups did not differ in the occurrence of any secondary end points. Severe hypotension occurred in 57% of patients receiving levosimendan and 48% of patients on placebo (P = .11); refractory hypotension defined as a mean arterial pressure <60% in spite of fluid and vasopressor therapy, occurred in 5 patients in the levosimendan and 1 patient in the placebo group (P = .12). Although more patients in the levosimendan group were treated with amiodarone in the operating room (levosimendan: 19 patients [11%]; placebo: 6 patients [4%]; P = .007), the incidence of arrhythmia (atrial fibrillation; levosimendan: 50%; placebo: 40%; P = .09) and conduction abnormalities (third-degree atrioventricular block; levosimendan: 4%; placebo: 9%; P = .08) was comparable. No difference was found in peak troponin at 24 and 48 hours as a surrogate parameter for myocardial injury. The effect of levosimendan, or rather the lack of it, was not affected by other predefined factors (prophylactic IABP, catecholamine support, preoperative β-receptor blockade, type of surgery, or severity of LV dysfunction).
In this study, Cholley et al 2 failed to detect a decrease in their primary and secondary end points when comparing levosimendan infusion with placebo, although there was a slight trend for less inotropic support required 48 hours after initiation of the infusion of levosimendan (P = .09). The follow-up at 180 days after surgery did not indicate a positive effect of levosimendan on mortality. The nonexisting difference in the troponin levels between the 2 treatment groups makes a protective effect of levosimendan on the myocardium unlikely. The estimated prevalence of the primary end point was 65%, and the observed prevalence was 61% in the placebo group. The hypothesis was that levosimendan decreases the prevalence of the end point to 50%, which was observed at 52%. However, the study was powered to detect a 15% absolute risk reduction and was, therefore, underpowered to statistically confirm the trend in clinical benefit conferred by levosimendan.
The LEVO-CTS trial, authored by Mehta et al, 3 included patients >18 years old with an LVEF <35% who were to undergo cardiac surgery with CPB. The 2 composite primary end points were as follows: (1) death through day 30, RRT through day 30, perioperative myocardial infarction (MI) through day 5, or the use of a cardiocirculatory assist device through day 5; or (2) death through day 30 or use of cardiocirculatory assist device through day 5.
Secondary end points included the following: low cardiac output syndrome, postoperative use of secondary inotropes at or beyond 24 hours after initiation of the study drug, and ICU LOS; multiple safety end points were also examined. A total of 882 patients were randomized in a 1:1 fashion to the levosimendan or placebo group, of whom 849 received the study drug and were included in the modified intention-to-treat analysis (levosimendan group: 428 patients; placebo group: 421 patients). The study drug was infused prior to skin incision after the arterial catheter was inserted at 0.2 µg/kg/min for 1 hour, followed by 0.1 µg/ kg/min for 23 hours. 18; 96% CI = 0.76 to 1.82; P = .45). Subgroup analysis revealed a trend for better outcomes with levosimendan in the low-LVEF group and better outcomes in the placebo group with a higher LVEF. The ICU LOS did not differ between the levosimendan and the placebo group. In the patients who had a pulmonary artery catheter in place (n = 359 and 340 for the levosimendan and placebo groups, respectively), the cardiac index was significantly higher in the levosimendan group (mean cardiac index ± SD: levosimendan, 2.86 ± 0.61 L/min/m 2 ; placebo, 2.68 ± 0.65 L/ min/m 2 ; P < .001). The incidence of low cardiac output syndrome and the secondary inotrope use was lower in the levosimendan group. No differences existed in the occurrence of safety end points. Mortality at 90 days occurred in 4.7% of patients in the levosimendan and 7.1% of patients in the placebo group (unadjusted hazard ratio = 0.64; 95% CI = 0.37 to 1.13; P = .12).
The authors conclude that the prophylactic use (ie, starting before skin incision) of levosimendan for patients with an impaired LVEF undergoing cardiac surgery is not associated with an increased rate of composite of death, RRT, and perioperative MI or the use of cardiocirculatory assist devices. Starting the levosimendan infusion just before incision may not provide enough time for effective prevention of myocardial injury. Furthermore, the underlying pathomechanisms of nonischemic and ischemia-induced left-ventricular dysfunction are different and may respond differently to calcium sensitizers. The authors acknowledge that about 3000 patients would need to be enrolled in a study adequately powered for detecting a difference in mortality, although there is a trend for a decreased 90-day mortality in the levosimendan group.
The data on levosimendan are complex, and numerous studies exist. However, as a result of the data from the 3 studies presented in this review, the routine use of prophylactic or therapeutic levosimendan cannot be recommended for patients with a decreased LVEF undergoing cardiac surgery. Each of the studies is underpowered to detect a difference in mortality. Additionally, the subgroups for which levosimendan is of greatest benefit have yet to be defined. While we await further studies and subgroup analyses, we contend with the fact that for now, levosimendan is not available in the United States because it is lacking FDA approval.
Methylprednisolone: Recovery and Delirium After Cardiac Surgery
The inflammatory response triggered by cardiac surgery with CPB can potentially cause organ dysfunction. Although high-dose steroids can suppress inflammation, its use in cardiac surgery has not led to an improvement in outcomes.
12-14 Royse et al 4 used a subset of data from the Steroid in caRdiac Surgery (SIRS) trial to test the hypotheses that high-dose methylprednisolone improves the quality of recovery and reduces the incidence of delirium in patients undergoing cardiac surgery. 4 A total of 555 patients were enrolled in this multicenter, double-blinded, randomized, placebo-controlled trial. Data for the evaluation of postoperative recovery were available for 482 patients and for the evaluation of delirium in 498 patients. The primary outcome was quality of recovery, and the secondary outcome included the cumulative incidence of delirium. Postoperative recovery was assessed using PostopQRS, which evaluates multiple domains: physiological, emotive, nociceptive, cognitive, and functional (activity of daily living [ADL]: ability to stand, dress, eat, walk). PostopQRS was performed before surgery, on postoperative days (PODs) 1, 2, and 3, and 1 and 6 months after surgery. The Confusion Assessment Method Intensive Care Unit (CAM-ICU Scale) was used to evaluate for delirium on PODs 1 to 3, with a positive score at any time classifying the patient as having experienced delirium. The intraoperative steroid management consisted of 2 doses of methylprednisolone 250 mg IV: one dose at anesthesia induction, and the second dose at initiation of CPB.
Regardless of the use of high-dose methylprednisolone, the overall recovery improved over time with no difference in the individual recovery domains (all P > .05): cognitive, physiological, emotive, nociceptive, and ADL recovery. The incidence of delirium was comparable in the control and the treatment groups (10% vs 8%; OR = 0.31; 95% CI = 0.73 to 2.48; P = .357). No difference in the recovery domains was found in a subgroup analysis comparing high with low cognitive baseline scores. The overall incidence of delirium between patients with low and normal baseline cognitive scores was 11% and 7% (OR = 0.63; 95% CI = 0.33 to 1.22; P = .91); however, patients with a low baseline cognitive score had a higher incidence of inattention (P = .001). In the subgroup of patients with normal baseline cognitive scores, the incidence of delirium was 7% in the treatment and 10% in the control groups (OR = 0.51; 95% CI = 0.57 to 4.22; P = .455); for patients in the low baseline group, the incidence of delirium was 7% in the treatment and 14% in the control group (OR = 0.456; 95% CI = 0.86 to 5.14; P = .13). Although patients experiencing delirium had a similar recovery at 6 months after surgery, they had poorer recovery in the cognitive (P = .004) domain at 6 months and physiological domain (P < .001) on POD 3.
Royse et al 4 conclude that intraoperative high-dose steroids do not improve postoperative recovery or decrease the incidence of delirium. Typically for cardiac surgery patients, about half of them had a low baseline cognitive score to begin with ("cognitive frailty"), which increases the likelihood of developing delirium. However, methylprednisolone did not prevent delirium in cognitively frail patients. At 6 months, the overall quality of recovery of patients experiencing delirium was not significantly different compared with patients not developing postoperative delirium, except for the domain of cognitive recovery, which was worse for patients with a positive CAM-ICU score. The study could not demonstrate a benefit to giving steroids to frail patients who are particularly susceptible to delirium. Further studies are warranted in this selective subgroup of patients. Until then, the routine administration of systemic high-dose methylprednisolone for patients undergoing cardiac surgery to prevent delirium and improve recovery cannot be recommended.
Reduction of Perioperative Transfusions in Cardiac Surgery Using Rotational Thromboelastometry
Patients presenting for cardiac surgery often suffer from comorbidities that result in anemia. In addition, the CPB circuit primed with crystalloid causes hemodilution, which can aggravate preoperative anemia. Anemia by itself is associated with an increase in complications-for example, prolonged ICU-LOS, stroke, AKI, reoperation, and mortality-and a number of studies have reported detrimental effects of blood product transfusions in patients undergoing cardiac surgery. [15] [16] [17] The use of ROTEM detects coagulation defects and has been shown to reduce perioperative transfusions. Mehaffey et al 5 changed the intraoperative management of their cardiac patients by introducing ROTEM for transfusion management and by using a CPB circuit with a low priming volume. 5 In their retrospective single-center study, the group investigated the effects of these changes on transfusions rate and on morbidity and mortality in patients undergoing cardiac surgery.
A total of 533 patients undergoing cardiac surgery with a CPB bypass circuit with a normal priming volume (1500 mL) without the use of ROTEM served as the control group. The intervention consisted of 2 stages: the first intervention was the reduction of the priming volume to 1100 mL for 290 patients ("streamlined CPB"); the second intervention was the use of ROTEM in addition to the use of streamlined CPB.
ROTEM was used to guide decision making according to standard reference ranges. However, in the absence of clinically significant bleeding determined by the surgeon, the patient was not transfused. The patients in the control and intervention groups were comparable in terms of demographics, starting hematocrit, platelet count, and the use of antiplatelet therapy. There was a slight increase in aortic cross-clamp time (4 minutes) over the study period and a transition from tranexamic acid to aminocaproic acid as an antifibrinolytic agent. The total amount of blood transfusion decreased with the interventions, with the circuit change having the largest effect on the reduction of platelet transfusion (control: 28%; streamlined CPB: 19.3%; P = .006) and ROTEM affecting intraoperative red blood cell transfusions the most (streamlined CBP: 17.9%; ROTEM: 11.3%; P = .008). The intervention group had a decreased utilization of blood products and a higher hematocrit intraoperatively (intervention: 27.1%; control: 26.0%; P = .0001) and at discharge (intervention: 29.1%; control: 28.2; P < .001). The observed to expected outcomes ratio was improved with the introduction of the streamlined CPB for renal failure (streamlined CPB: 0.47; control: 0.76; P = .02), and the introduction of ROTEM reduced the need of surgical reexplorations (ROTEM: 0.4; control: 0.73; P = .01).
This study was able to show that the interventions of decreasing the CPB priming volume and the use of ROTEM can decrease the overall use of blood products, although in this study, it did not translate to an improvement in mortality. The authors speculate that ROTEM shifted the management of coagulopathy from the use of FFP to cryoprecipitate. However, it appears that the reduction in cryoprecipitate use was associated with the use of the streamlined CPB, rather than the addition of ROTEM to management. A shortcoming of this study is that the authors do not describe the transfusion triggers for blood products in the control group prior to the introduction of ROTEM. The switch from tranexamic acid to aminocaproic acid might have played a role in the reduction of blood products transfused, something the authors did not control for. Avoiding hemodilution by minimizing the priming volume of the CPB circuit is a strategy with few side effects to minimize transfusions. It is prudent to make an informed decision on blood product transfusion based on hematological and coagulation data, with ROTEM having a great potential to guide the cardiothoracic anesthesiologist. However, further randomized, controlled, multicenter studies comparing ROTEM with established transfusion protocols are warranted.
TAVR Versus SAVR in IntermediateRisk Patients
Since the inception of TAVR as an alternative to SAVR in patient with aortic stenosis, the technique has evolved, and outcome data have become available in the past 1 year. Whereas initially TAVR was reserved for patients with a risk profile prohibitive for undergoing SAVR, the indications for the transcatheter approach have been relaxed. Two reports came out in 2017 comparing the 2-year outcomes of TAVR compared with SAVR in intermediate-risk patients. 6, 7 Reardon et al 6 compared in the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial the safety and efficacy of TAVR with a self-expanding bioprosthesis with SAVR in intermediate-risk patients. The primary end point was a composite of death from any cause or disabling stroke at 2 years after the procedure. Secondary end points were major cardiovascular or cerebrovascular events: death from any cause, MI, stroke, and reintervention. Health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a 23-item questionnaire covering 5 key domains of health status (physical function, social function, symptoms, selfefficacy and knowledge, and quality of life [QOL]), with scores from 0 to 100 (higher scores = better QOL). A total of 1746 patients with severe aortic stenosis and an estimated 30-day mortality risk of 3% to 15%, according to the Society of Thoracic Surgeons (STS) criteria, underwent 1:1 randomization. Self-expanding valves were used (84% CoreValve, 16% Evolut R, Medtronic), either via the transfemoral route, the transsubclavian route, or the direct aortic approach. Very few patients crossed over from the TAVR group to SAVR and vice versa, leaving 863 patients in the TAVR group and 794in the SAVR. The median STS score was 4.5% ± 1.6% (intermediate risk), and the mean age was 79.8 ± 6.2 years, with most patients having other comorbidities: for example, diabetes, chronic lung disease, and frailty. The incidence of the primary end point was 12.6% in the TAVR and 14.0% in the SAVR group at 2 years (95% credible interval [Bayesian analysis], −4.7% to 2.7%, posterior probability of noninferiority, >0.99), with the intention-to-treat analysis revealing similar results. Death occurred in 11.4% of the TAVR and 11.6% of the SAVR patients at 2 years (95% credible interval for difference, −3.8% to 3.3%), with a difference in the rate of disabling stroke between the groups. The KCCQ summary score as QOL indicator improved significantly in both groups at 2 years, with a higher proportion of patients with improvement in the TAVR group at 1 month postprocedure. On echocardiography, the TAVR patients had lower mean gradient across the aortic valve (and a larger valve area) compared with the SAVR group. Moderate or severe aortic insufficiency was more prevalent in the TAVR group at 1 year (TAVR: 5.3%; SAVR: 0.6%; 95% credible interval for difference, 2.8% to 6.8%). Surgery was associated with a higher risk of atrial fibrillation (TAVR: 12.9%; SAVR: 43.4%; 95% credible interval for difference, −34.7% to −26.4%), AKI (TAVR: 1.7%; SAVR: 4.4%; 95% credible interval for difference, −4.4% to −1.0%), and transfusion requirements (TAVR: 12.5%; SAVR: 41.1%; 95% credible interval for difference, −24.4% to −32.5%). The risk of requiring a permanent pacemaker is higher in the TAVR group (TAVR: 25.9%; SAVR: 6.6%; 95% credible interval for difference, 15.9 to 22.7), as is the risk of major vascular complications (TAVR: 6.0%; SAVR: 1.1%; 95% credible interval for difference, 3.2% to 6.7%)
The results of the SURTAVI trial show that TAVR was noninferior to SAVR in patients with an intermediate mortality risk from heart surgery when followed over 2 years. Interestingly, the TAVR valves have better echocardiographic flow dynamics, and no valve showed signs of structural valve deterioration at the end of the observation period. Although TAVR is noninferior in terms of primary and secondary end points in this study, each procedure has its own set of complications (TAVR: pacemaker requirement, vascular complications; SAVR: transfusion requirements, AKI, atrial fibrillation).
The second 2-year comparison of TAVR versus SAVR in patients at an intermediate risk for cardiac surgery is presented by Baron et al, 7 using data from the Placement of Aortic Transcatheter Valve (PARTNER) 2 Cohort. The valve used in this trial was the Sapien XT valve (Edwards LifeSciences), and a transthoracic access was allowed. The participants' health status was assessed at baseline, 1 month, 1 year, and 2 years, using different questionnaires: the KCCQ, the KCCQ-OS with a single overall summary score correlating with the New York Heart Association (NYHA) functional class, the Medical Outcomes Study Short-Form 36, and the European Quality of Life 5 dimensions (EQ-5D-5L) health status classification system. Health status was evaluated in a primary analysis comparing the patients randomized on an intention-to-treat analysis; a secondary analysis compared them according to their per-protocol assignment. The primary end point was the KCCQ-OS score, with all other QOL scores being secondary end points. The ordinal values of the KCCQ-OS score were divided into categories to allow for categorical analysis to provide further perspective on clinically relevant changes: death, worse (decrease from baseline >5 points), no change (change between −5 and <5 points), mild improved (increase 5 to <10 points), moderately improved (increase between 10 and <20 points), and substantially improved (increase >20 points).
A total of 1833 patients were available for a 1:1 randomization, resulting in 950 TAVR and 883 SAVR patients. The mean age was 81.4 ± 6.8 years. The calculated mean mortality using the STS score was 5.8% ± 2.1% in the TAVR group and 5.8% ± 1.9% in the SAVR group, putting the patients in the intermediate-risk group for cardiac surgery. The 24% of patients in the TAVR group who required transthoracic access had a higher prevalence of peripheral artery disease, prior CABG surgery, and prior stroke. After TAVR and SAVR, the health status increased, as reflected by a mean improvement of 16 to 22 points on the KCCQ-OS scale at 1 year postprocedure. Similar improvements were seen at 2 years post-TAVR/SAVR. However, at 1 month, the transfemoral TAVR group had greater improvements in the KCCQ-OS scale than the SAVR group. These differences disappeared 1 to 2 years after the procedure. There were no differences in the KCCQ-OS between the transthoracic TAVR and the SAVR group at 1 month, 1 year, or 2 years postprocedure. Whereas the improvement in the KCCQ-OS was greater in the transfemoral TAVR group compared with the SAVR group at the 1-month follow-up, this benefit was not seen in the transthoracic TAVR population. At the 1-and 2-year follow-ups, almost half the patients had a substantial improvement in the KCCQ-OS score, with no difference between the SAVR and TAVR in both the transfemoral and the transthoracic groups.
This study shows that the 2-year health status in intermediate-risk patients undergoing SAVR or TAVR is comparable, independent of TAVR access site. However, at 1 month, the transfemoral access for TAVR offers a better health status than SAVR, indicating a more rapid improvement in health status. More than 60% of the surviving patients experience a clinically meaningful improvement (>10 points) in the KCCQ-OS score at 2 years. The benefits of TAVR over SAVR disappear when a transthoracic approach is necessary because the improvement in health status in these groups is comparable at all time points.
LVADs: Centrifugal-Flow Versus Axial-Flow Systems
With LVADs implanted more frequently in patients with HF as destination therapy, bridge to transplant, bridge to candidacy for transplant, or bridge to recovery, we will see a steady increase in cases needing a cardiac anesthesiologist. Two articles published in 2017 compare axial versus centrifugal-flow devices in terms of complications: the ENDURANCE and the MOMENTUM 3 trial. 18, 19 In the ENDURANCE trial, a randomized controlled, multicenter study, Rogers et al 18 compared the HeartWare centrifugal-flow LVAD (study group) with the HeartMate II axial-flow pump (control group) in patients with severe HF in spite of optimum medical management who were not candidates for heart transplantation (destination therapy). 18 Eligibility criteria were LVEF <25%, NYHA functional class IIIB (HF symptoms with minimal activity, recent dyspnea at rest) or VI (HF symptoms at rest), and ineligibility for heart transplantation. The Interagency Registry for Mechanical Assisted Circulatory Support (INTERMACS) patient profile was used for classifying the severity of illness. Additional assessments included the KCCQ (score 0-100, higher numbers reflecting better health status), the European Quality of Life 5 Dimensions Visual Analog Scale (EQ-5D VAS), the 6-minute walk distance, NYHA functional class, and neurological status (modified Rankin scale: 0-6, with 0 for no symptoms and 6 for death; score ≥4: disabling stroke). Follow-up visits were scheduled at 3, 6, 12, 18, and 24 months for testing device performance, laboratory data, and medication recording. Functional capacity and QOL were assessed 3, 6, 12, and 24 months after implantation. The primary end point was a composite of 2-year survival free from disabling stroke assessed 24 weeks after the stroke, with the patient being alive with the original device, or being transplanted, or having recovered from HF with explantation of the LVAD. Secondary end points included major adverse events, overall survival, changes in the KCCQ score and the EQ-5D VAS, and changes in the NYHA functional class or the 6-minute walk distance. The study was designed as a noninferiority trial to the control device (HeartMate II). In the intention-to-treat analysis, 297 patients were randomized to the study group (HeartWare) and 148 to the control group (HeartMate II). The control group was slightly older, whereas more patients in the study group had severe tricuspid regurgitation. Tricuspid valve repair/replacement rates were similar (study group: 11.1%; control group: 12.1%; P = .522). The intention-totreat analysis showed noninferiority of the study device, with similar results in per-protocol analysis: the primary end point was reached in 55.4% in the study and 59.1% in the control group (P = .01 for noninferiority). The estimated survival rates free from disabling stroke or need for device replacement at 24 months were 55.0% in the study group and 57.4% in the control group (P = .67 by the logrank test). More patients in the control group had device malfunctions requiring exchange, LVAD explantations, or urgent transplantations. No difference existed between the groups in the incidence of major bleedings, arrhythmias, AKI, and infections (including drive-line infections). However, more participants in the study group suffered groups. The risk of bleeding and drive-line infection was comparable between the centrifugal-flow and axial-flow devices, and the risk of right HF is either the same (HeartMate 3, MOMENTUM 3 trial) or even higher (HeartWare, ENDURANCE trial) with centrifugal-flow pumps. The stroke risk appears to be about the same (HeartMate 3) or higher (HeartWare) with centrifugalflow pumps. Nevertheless, the studies still indicate that centrifugal-flow pumps are superior to axial-flow pumps, especially with regard to pump thrombosis because the risk for such an event to happen increases with the duration of cardiocirculatory assist device therapy. It would be interesting to compare the 2 centrifugal-flow pumps with each other, especially over a longer time. We are curious to see more studies comparing long-term outcomes with the new LVAD devices!
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